Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 10, 2024 08:00 ET | Source: iBio, Inc.

iBio and AstralBio Provide Update on Myostatin Program for Obesity

SAN DIEGO, Oct. 10, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO), an AI-driven innovator of precision antibody immunotherapies, today provided an update on the myostatin program for...
September 20, 2024 16:05 ET | Source: iBio, Inc.

iBio Reports Fiscal Year 2024 Financial Results and Provides Corporate Update

SAN DIEGO, Sept. 20, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO), an AI-driven innovator of precision antibody immunotherapies, today announced its financial results for the fiscal year ended...
September 03, 2024 07:00 ET | Source: iBio, Inc.

iBio to Participate in Upcoming Investor Conferences

SAN DIEGO, Sept. 03, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO), an AI-driven innovator of precision antibody immunotherapies, announced today that CEO and Chief Scientific Officer, Martin...
August 12, 2024 16:30 ET | Source: iBio, Inc.

iBio Expands Executive Leadership Team with Appointment of Kristi Sarno as Senior Vice President of Business Development

SAN DIEGO, Aug. 12, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO), an AI-driven innovator of precision antibody immunotherapies, announced today the appointment of Kristi Sarno as senior vice...
June 03, 2024 07:00 ET | Source: iBio, Inc.

iBio Closes Sale of Manufacturing Facility in Texas

– The sale of the facility eliminates $13.2M of secured debt – – Completes iBio’s transition to an AI and precision biologics innovation company - SAN DIEGO, June 03, 2024 (GLOBE NEWSWIRE) --...
May 13, 2024 16:05 ET | Source: iBio, Inc.

iBio Reports Fiscal Third Quarter 2024 Financial Results and Provides Corporate Update

Strengthened cash position with investment by healthcare specialist investorsExpanding into cardio-metabolic space through AstralBio collaboration BRYAN, Texas and SAN DIEGO, May 13, 2024 ...
March 27, 2024 07:00 ET | Source: iBio, Inc.

iBio and AstralBio Announce Transformative AI drug discovery Collaboration to Rapidly Develop Novel Antibodies for Obesity and Cardiometabolic Diseases

– Leading AI and precision biologics innovators to build a diverse set of novel best-in-class obesity treatments – – iBio to use its patented generative AI/Machine Learning platform to discover,...
March 26, 2024 19:35 ET | Source: iBio, Inc.

iBio Announces $15.0 Million Private Placement

– Purchase price of $2.85 represents a premium of 148+% to last close – BRYAN, Texas and SAN DIEGO, March 26, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an...
February 26, 2024 07:45 ET | Source: iBio, Inc.

iBio Announces Sale of Preclinical PD-1 Agonist Antibody Program to Otsuka

– Deal includes $1 million upfront and potential future milestone payments – – iBio’s proprietary therapeutic pipeline will now be comprised entirely of promising immuno-oncology candidates – ...
January 16, 2024 08:15 ET | Source: iBio, Inc.

iBio Announces Participation in 23rd Annual PepTalk Conference

BRYAN, Texas and SAN DIEGO, Jan. 16, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, announced today that...